Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 5 | 2023 | 235 | 0.730 |
Why?
|
| Safety Management | 1 | 2008 | 56 | 0.330 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 268 | 0.300 |
Why?
|
| Emphysema | 1 | 2023 | 22 | 0.230 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 30 | 0.230 |
Why?
|
| Muscle, Smooth | 4 | 2010 | 354 | 0.200 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 165 | 0.200 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 53 | 0.180 |
Why?
|
| Mediastinum | 1 | 2019 | 46 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2600 | 0.170 |
Why?
|
| Patient Compliance | 1 | 2020 | 227 | 0.170 |
Why?
|
| Internship and Residency | 3 | 2017 | 1004 | 0.150 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 123 | 0.150 |
Why?
|
| Serum Response Factor | 2 | 2010 | 44 | 0.150 |
Why?
|
| Professional Misconduct | 1 | 2017 | 25 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 219 | 0.150 |
Why?
|
| Lung | 2 | 2023 | 1170 | 0.150 |
Why?
|
| Video Recording | 2 | 2017 | 190 | 0.140 |
Why?
|
| Internal Medicine | 2 | 2017 | 347 | 0.140 |
Why?
|
| Advance Care Planning | 1 | 2016 | 43 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2019 | 530 | 0.130 |
Why?
|
| Ethics, Medical | 1 | 2017 | 306 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1673 | 0.120 |
Why?
|
| Education | 1 | 2013 | 58 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2010 | 75 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 848 | 0.110 |
Why?
|
| Hospitalists | 1 | 2013 | 131 | 0.100 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 334 | 0.090 |
Why?
|
| Physicians | 1 | 2017 | 673 | 0.090 |
Why?
|
| Humans | 16 | 2023 | 86601 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2013 | 751 | 0.080 |
Why?
|
| Aged | 5 | 2022 | 18402 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2010 | 579 | 0.070 |
Why?
|
| Asthma | 2 | 2003 | 955 | 0.060 |
Why?
|
| Middle Aged | 5 | 2022 | 25017 | 0.060 |
Why?
|
| Male | 6 | 2023 | 40956 | 0.060 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 25 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8475 | 0.060 |
Why?
|
| Actins | 2 | 2003 | 451 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 2767 | 0.060 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2003 | 77 | 0.060 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2003 | 83 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2002 | 49 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2003 | 283 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 937 | 0.050 |
Why?
|
| Prone Position | 1 | 2022 | 56 | 0.050 |
Why?
|
| Bronchi | 1 | 2003 | 229 | 0.050 |
Why?
|
| Wakefulness | 1 | 2022 | 134 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 361 | 0.050 |
Why?
|
| Female | 5 | 2022 | 44507 | 0.040 |
Why?
|
| Gene Expression | 1 | 2003 | 1284 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1823 | 0.040 |
Why?
|
| Adult | 3 | 2022 | 25640 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 726 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 277 | 0.040 |
Why?
|
| Genome, Human | 1 | 2002 | 756 | 0.040 |
Why?
|
| Hypoxia | 1 | 2022 | 641 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 930 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 920 | 0.040 |
Why?
|
| United States | 2 | 2019 | 6665 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 740 | 0.030 |
Why?
|
| Outpatients | 1 | 2016 | 94 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 999 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1239 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1860 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1531 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1185 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1801 | 0.030 |
Why?
|
| Educational Technology | 1 | 2013 | 14 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 2377 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2022 | 6501 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 539 | 0.030 |
Why?
|
| Dogs | 2 | 2003 | 685 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 3674 | 0.020 |
Why?
|
| alpha Karyopherins | 1 | 2010 | 10 | 0.020 |
Why?
|
| Dimerization | 1 | 2010 | 143 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 134 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 5974 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 379 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 7988 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 305 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 425 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2501 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 557 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2003 | 1135 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2003 | 2818 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1456 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 2468 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 1749 | 0.010 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2003 | 12 | 0.010 |
Why?
|
| Thiazolidines | 1 | 2003 | 17 | 0.010 |
Why?
|
| Muscle Cells | 1 | 2003 | 18 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 2003 | 64 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 60 | 0.010 |
Why?
|
| Elasticity | 1 | 2003 | 94 | 0.010 |
Why?
|
| Histamine | 1 | 2003 | 126 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 2003 | 88 | 0.010 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2003 | 76 | 0.010 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 2003 | 111 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 131 | 0.010 |
Why?
|
| Trachea | 1 | 2003 | 293 | 0.010 |
Why?
|
| rho-Associated Kinases | 1 | 2003 | 159 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 393 | 0.010 |
Why?
|
| Respiration | 1 | 2003 | 262 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2002 | 351 | 0.010 |
Why?
|
| Pyridines | 1 | 2003 | 309 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2002 | 201 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 379 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 450 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 639 | 0.010 |
Why?
|
| Mutation | 1 | 2010 | 3967 | 0.010 |
Why?
|
| Animals | 3 | 2003 | 26581 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1961 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 853 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 2330 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3030 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 3241 | 0.010 |
Why?
|